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SUMMARY
Background: Use of polyclonal anti-hepatitis B surface antigen immunoglobulin (HBIg) has been shown to reduce hepatitis B
virus (HBV) recurrence after liver transplantation (LT) and to decrease the frequency of acute cellular rejection (ACR). However, the
protective role of HBIg against ACR remains controversial, since HBV infection has been also associated with a lower incidence of
ACR. Aim: To assess the relationship between HBIg immunoprophylaxis and the incidence of rejection after LT. Methods: 260
patients (158 males, 43 ± 14 years old) submitted to LT were retrospectively evaluated and divided into three groups, according to the
presence of HBsAg and the use of HBIg. Group I was comprised of HBsAg-positive patients (n = 12) that received HBIg for more
than 6 months. Group II was comprised of HBsAg-positive patients that historically have not received HBIg or have been treated
irregularly for less than 3 months (n = 10). Group III was composed of 238 HBsAg-negative subjects that have not received HBIg.
Results: HBIg-treated patients (group I) had significantly less ACR episodes, when compared to group II and III. No differences
between groups II and III were observed. Conclusions: Long-term HBIg administration contributes independently to reduce the
number of ACR episodes after LT.
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INTRODUCTION
Long-term prophylactic administration of polyclonal anti-hepatitis
B surface antigen immunoglobulin (HBIg) has been shown to reduce
hepatitis B virus (HBV) recurrence and to improve survival after liver
transplantation (LT) for chronic hepatitis B (CHB)7,8,13, as well as to
decrease the frequency of HCV viremia after LT in patients with hepatitis
B and C coinfection4. Apart from its effect on recurrent viral diseases,
HBIg administration was also associated with lower incidence of acute
hepatic rejection (ACR) and chronic ductopenic rejection (CDR)
after LT3. In this respect, patients submitted to liver transplantation
for CHB were shown to be less susceptible to both ACR and CDR
than non-HBV transplanted subjects1,3. However, it is not yet clear
whether this reduced rate of rejection observed in those patients is
related, in fact, to HBV infection or to the long-term administration of
HBIg.
The purpose of the present study was to investigate the relationship
between HBIg immunoprophylaxis and the incidence of ACR and CDR
in patients with CHB submitted to LT with and without HBIg
immunoprophylaxis.
PATIENTS AND METHODS
Subjects: Two-hundred and sixty patients (158 males, 43 ± 14 years
old) that underwent liver transplantation between September 1985 and
June 1999 were retrospectively evaluated and divided into three groups
according to the presence of HBsAg and the use of HBIg. Twenty-two
patients had CHB of whom all were HBsAg positive, and nine had
HBeAg. Group I was comprised of HBsAg-positive patients who received
HBIg for more than 6 months to achieve HbsAb levels  100 IU/L (n =
12). Group II was composed of HBsAg-positive patients who historically
have not received HBIg immunoprophylaxis (n = 7) or had been treated
irregularly with HBIg for less than 3 months (n = 3). Group III included
238 HBsAg-negative subjects who underwent LT due to other chronic
liver diseases.
The frequencies of ACR and CDR and the number of ACR episodes
during the first six months after liver transplantation were recorded in
all patients.
Immunosuppressive regimen: All patients used triple-drug
immunosuppression that consisted of cyclosporin, prednisone and
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azathioprine. All acute allograft rejection episodes were treated with
intravenous bolus of 1-3 g of methylprednisolone with or without an oral
recycle of prednisone. All acute allograft rejection episodes that were
resistant to corticosteroid therapy were subsequently treated with OKT3.
HBIg regimen: Immunoprophylaxis with HBIg was begun during
the anhepatic phase with 10,000 IU of HBIg intravenously. The frequency
of HBIg administration was based on the HBsAb titers for maintaining
levels above 100 IU/L in the long-term follow-up. As previously stated,
all patients in group I received HBIg therapy for more than six months,
while three patients in group II received immunoprophylaxis for no longer
than three months.
Diagnosis of rejection: The diagnosis of ACR was based on the
presence of abnormal liver enzymes and pathological evidence of
rejection that included the presence of mixed portal infiltrate associated
with bile duct and/or endothelial cell injuries. CDR was defined by the
histological findings of vanishing interlobular bile ducts in greater than
50% of the portal tracts and/or histological findings of foam cell
arteriopathy2.
Statistical analysis: The cumulative rate of ACR and CDR and the
frequency of ACR episodes in the first six months after LT were
determined in patients from groups I, II and III, and were compared
using either the Kruskal-Wallis test or the Fisher exact probability test,
when appropriate. A p value < 0.05 was considered significant. Clinical
and laboratory data are expressed in text and tables as percentages or
median and range.
RESULTS
The frequency of ACR in groups I, II and III at six months was 25%,
70% and 56%, respectively (p = NS) (Table 1).
Patients treated with HBIg (group I) had significantly less ACR
episodes when compared to group II (0.3 ± 0.5 vs. 0.9 ± 0.7, p = 0.02)
and group III (0.3 ± 0.5 vs. 0.7 ± 0.7, p = 0.03). No differences between
groups II and III were observed (Table 2).
Time interval until the first episode of rejection, rates of steroid-
resistant rejection and CDR were not statistically different between those
groups (Table 3).
DISCUSSION
The findings of the present study indicate that the use of HBIg, for
the purpose of preventing recurrence of hepatitis B after LT, is also
associated with fewer episodes of ACR in the first six months after
surgery. The cumulative incidence of ACR was also shown to be reduced
in HBIg-treated subjects, when compared to other patients submitted to
LT, but the difference was not significant. The decrease in the number of
ACR was related to HBIg administration and not to previous CHB and/
or HBV recurrence following LT, because no differences in the frequency
of ACR episodes were noted between patients submitted to LT for
hepatitis B, who had not been treated with HBIg, and patients transplanted
with other chronic liver disorders.
Two previous studies have reported reduced frequencies of rejection
in patients submitted to LT for hepatitis B, but were unable to distinguish
whether these findings were secondary to HBIg administration or to
previous hepatitis B infection, and/or recurrence after LT1,3.
ADAMS et al.1 have reported lower rates of ACR in patients
submitted to LT due to chronic hepatitis B but the authors have not
examined the possible role of HBIg in this setting. Additionally, FARGES
et al.3 have investigated the frequency of hepatic allograft rejection in
patients submitted to LT due to CHB and other chronic liver diseases,
including alcoholic liver disease (ALD), primary biliary cirrhosis, primary
sclerosing cholangitis, autoimmune hepatitis, and chronic hepatitis C.
Most of the patients with CHB were HBV DNA negative and have
received long-term HBIg immunoprophylaxis with no signs of HBV
recurrence on the graft. The actuarial incidence of ACR and CDR was
significantly decreased in the patients transplanted for CHB, when
compared to subjects with other chronic liver diseases. The frequency
of ACR, but not CDR, was also reduced in patients with ALD prior to
LT. As this decrease was associated with an increase in septic
complications, it was hypothesized that the decreased rate of ACR
observed in this group of patients could be due to diminished immune
responsiveness, possibly related to previous alcohol consumption. In
respect to patients transplanted for CHB, the only possibility raised by
the authors to explain the observed lower frequency of ACR was the use
of polyclonal immunoglobulins. In this regard, a reduced incidence of
Table 1
Frequency of acute cellular rejection in groups I, II and III
N Frequency of acute cellular rejection
Group I 3 25%
Group II 7 70%
Group III 133 56%
p = NS
Table 3
Timing of the first acute allograft rejection episode and frequencies of steroid-
resistant acute rejection and chronic rejection in groups I, II and III
Timing of the first Steroid-resistant Chronic
episode of acute Acute rejection ductopenic
allograft rejection (%) rejection
(days) (%)
Group I 6.9 [6.9-6.9] 0 0
Group II 8.1 [6.0-12.9] 0 0
Group III 6.9 [3.0-99] 12% 4%
p = NS
Table 2
Number of acute cellular rejection episodes in groups I, II and III
Number of AHR episodes
Group I 0.3 ± 0.5a
Group II 0.9 ± 0.7b
Group III 0.7 ± 0.7c
a,b
 p = 0.02, a,c p = 0.03
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ACR, but not of CDR, was also associated, in the same study, with the
prophylactic use of polyclonal anti-cytomegalovirus immunoglobulin3.
The reasons for the reduced rates of ACR observed in HBIg-treated
patients remain largely unknown. The use of human polyclonal
immunoglobulins has been previously shown to influence the timing of
experimental hyperacute xenograft rejection and to decrease in vivo and
in vitro T cell responses in sensitized renal transplant candidates5,9,10.
These effects are possibly due to the presence of anti-idiotypes in these
preparations directed against preformed antidonor antibodies9. However,
HBIg therapy has been associated with reduced rates of ACR, that is
thought to be mediated by cytotoxic T cells against donor alloantigens
and not by preexisting antidonor antibodies14. It is well known that
polyclonal antilymphocyte immunoglobulins and monoclonal anti-CD3
antibodies are effective agents used in the prevention and the treatment
of ACR, because of their marked effect on circulating cytotoxic T cells11.
It is therefore possible to speculate that polyclonal immunoglobulin
preparations could influence to a lesser extent cytotoxic T cell responses
through similar immunoregulatory properties.
These findings all together, suggest that HBIg administration may
contribute to reduce the number of ACR episodes after LT. This reduction
seems to be related to HBIg prophylaxis since HBsAg-positive patients
who did not receive HBIg in the present study had similar rates of
rejection, when compared to their HBsAg-negative counterparts.
However, it is important to emphasize that other studies evaluating the
influence of etiology in the frequency of rejection have not shown reduced
rates of rejection in patients transplanted for CHB14,15. As those reports
have not addressed the influence of HBIg prophylaxis on the frequency
of ACR, it would be therefore interesting to reassess the effect of HBIg
therapy in this setting.
Several centers are now employing lamivudine alone or in association
with HBIg prophylaxis for the prevention of HBV recurrence on the
graft6,12. It would be very interesting to compare the incidence of rejection
in those subjects receiving either lamivudine or HBIg prophylaxis after
LT in order to settle this issue.
RESUMO
A imunoglobulina policlonal humana anti-antígeno de superfície
da hepatite B reduz a freqüência da rejeição aguda após
transplante de fígado
Introdução: O emprego da imunoglobulina policlonal anti-antígeno
de superfície da hepatite B (HBIg) tem reduzido a recorrência da hepatite
B após transplante hepático (TH), assim como também a freqüência de
rejeição celular aguda (RCA). No entanto, o papel protetor da HBIg
contra a RCA permanece controverso, pois a própria infecção por vírus
B foi também associada a menor incidência de RCA. Objetivos: Verificar
a relação entre HBIg e a freqüência de RCA após TH. Métodos: 260
pacientes (158 do sexo masculino, com 43 ± 14 anos) submetidos a TH
foram avaliados, retrospectivamente, e divididos em três grupos de acordo
com a presença de AgHBs e uso de HBIg. O grupo I foi constituído por
12 pacientes com AgHBs que receberam HBIg por mais de 6 meses; o
grupo II foi formado por 10 pacientes com AgHBs que não receberam
HBIg regularmente; o grupo III foi composto por 238 indivíduos sem
AgHBs que não receberam HBIg. Resultados: Nos pacientes do grupo
I houve freqüência significantemente menor de episódios de RCA, em
comparação ao que se observou nos grupos II e III. Nenhuma diferença
ocorreu entre os grupos II e III. Conclusões: A administração profilática
de HBIg contribui independentemente para reduzir a freqüência dos
episódios de RCA após a realização de TH.
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